Loading...

William J Murphy

TitleProfessor
InstitutionUniversity of California Davis
DepartmentDermatology
AddressIRC #1612
CA 95817
Phone916-703-9397
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Immunoregulatory and effector roles of natural killer cell subsets
    NIH/NHLBI R01HL140921Jan 1, 2018 - Dec 31, 2021
    Role: Principal Investigator
    Multispecies Comparison of the Impact of Obesity on GVHD/GVT
    NIH/NCI R01CA214048Jan 12, 2017 - Dec 31, 2021
    Role: Principal Investigator
    1 of 3 Interdisciplinary Collaboratory for Enhancing Translational Therapeutics Utilizing Biologically, Immunologically, and Metabollically Relevant Models of Breast Cancer
    NIH/NCI R01CA195904May 15, 2015 - Apr 30, 2018
    Role: Principal Investigator
    Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies
    NIH/NCI R01CA189209Mar 6, 2015 - Feb 29, 2020
    Role: Principal Investigator
    Positive and Negative Regulation of Natural Killer Cells After BMT
    NIH/NHLBI R01HL089905Jul 18, 2007 - Nov 30, 2015
    Role: Principal Investigator
    Neuroendocrine Hormones to Promote Immune Reconstitution
    NIH/NIA R01AG022661Aug 1, 2003 - Jul 31, 2009
    Role: Principal Investigator
    Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets
    NIH/NCI R01CA102282Jul 1, 2003 - Apr 30, 2014
    Role: Principal Investigator
    Immunotherapy by CD40 stimulation and IL-2 against Cancer
    NIH/NCI R01CA095572Sep 1, 2002 - Jan 31, 2018
    Role: Principal Investigator
    Immunotherapy using NK cells to promote engraftment
    NIH/NCI R01CA093527Sep 1, 2002 - Aug 31, 2007
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2018 Nov 12. PMID: 30420753.
      View in: PubMed
    2. Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Culter CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar B. Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease. Blood. 2018 Oct 02. PMID: 30279226.
      View in: PubMed
    3. Canter RJ, Murphy WJ. A possible new pathway in natural killer cell activation also reveals the difficulty in determining human NK cell function in cancer. J Immunother Cancer. 2018 Aug 07; 6(1):79. PMID: 30086799.
      View in: PubMed
    4. Chavez M, Silvestrini MT, Ingham ES, Fite BZ, Mahakian LM, Tam SM, Ilovitsh A, Monjazeb AM, Murphy WJ, Hubbard NE, Davis RR, Tepper CG, Borowsky AD, Ferrara KW. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. Theranostics. 2018; 8(13):3611-3628. PMID: 30026870.
      View in: PubMed
    5. Canter RJ, Grossenbacher SK, Foltz JA, Sturgill IR, Park JS, Luna JI, Kent MS, Culp WTN, Chen M, Modiano JF, Monjazeb AM, Lee DA, Murphy WJ. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. J Immunother Cancer. 2017 Dec 19; 5(1):98. PMID: 29254507.
      View in: PubMed
    6. Zamora AE, Aguilar EG, Sungur CM, Khuat LT, Dunai C, Lochhead GR, Du J, Pomeroy C, Blazar BR, Longo DL, Venstrom JM, Baumgarth N, Murphy WJ. Licensing delineates helper and effector NK cell subsets during viral infection. JCI Insight. 2017 May 18; 2(10). PMID: 28515356.
      View in: PubMed
    7. Grossenbacher SK, Aguilar EG, Murphy WJ. Leveraging natural killer cells for cancer immunotherapy. Immunotherapy. 2017 05; 9(6):487-497. PMID: 28472904.
      View in: PubMed
    8. Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JI, Culp WTN, Sparger EE, Rebhun RB, Monjazeb AM, Murphy WJ, Canter RJ. Canine cancer immunotherapy studies: linking mouse and human. J Immunother Cancer. 2016; 4:97. PMID: 28031824.
      View in: PubMed
    9. McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, Peterson N, MacDonald KP, Hill GR, Luznik L, Serody JS, Murphy WJ, Maillard I, Munn DH, Turka LA, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Blazar BR. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7. PMID: 27385791; PMCID: PMC4990850 [Available on 08/18/17].
    10. Grossenbacher SK, Canter RJ, Murphy WJ. Natural killer cell immunotherapy to target stem-like tumor cells. J Immunother Cancer. 2016; 4:19. PMID: 27096096; PMCID: PMC4835831.
    11. Canter RJ, Grossenbacher SK, Ames E, Murphy WJ. Immune targeting of cancer stem cells in gastrointestinal oncology. J Gastrointest Oncol. 2016 Apr; 7(Suppl 1):S1-S10. PMID: 27034806; PMCID: PMC4783622.
    12. Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR, Nyuydzefe MS, Weiss JM, Chen W, Trzeciak A, Serody JS, Aguilar EG, Murphy WJ, Maillard I, Munn D, Koreth J, Cutler CS, Antin JH, Ritz J, Waksal SD, Zanin-Zhorov A, Blazar BR. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54. PMID: 26983850.
      View in: PubMed
    13. Kheirolomoom A, Ingham ES, Mahakian LM, Tam SM, Silvestrini MT, Tumbale SK, Foiret J, Hubbard NE, Borowsky AD, Murphy WJ, Ferrara KW. CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. J Control Release. 2015 Dec 28; 220(Pt A):253-264. PMID: 26471394; PMCID: PMC4688109 [Available on 12/28/16].
    14. Shanker A, Pellom ST, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res. 2015 Dec 15; 75(24):5260-72. PMID: 26494122.
      View in: PubMed
    15. Sckisel GD, Mirsoian A, Bouchlaka MN, Tietze JK, Chen M, Blazar BR, Murphy WJ. Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. Cancer Immunol Immunother. 2015 Dec; 64(12):1541-52. PMID: 26423422; PMCID: PMC4782757.
    16. Sckisel GD, Bouchlaka MN, Monjazeb AM, Crittenden M, Curti BD, Wilkins DE, Alderson KA, Sungur CM, Ames E, Mirsoian A, Reddy A, Alexander W, Soulika A, Blazar BR, Longo DL, Wiltrout RH, Murphy WJ. Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity. Immunity. 2015 Aug 18; 43(2):240-50. PMID: 26231116; PMCID: PMC4770886.
    17. Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94. PMID: 25852057; PMCID: PMC4481596.
    18. Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknect E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, Mak TW, van den Brink M, Zeiser R, Blazar BR. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015 May 21; 125(21):3335-46. PMID: 25814530; PMCID: PMC4440885.
    19. Mirsoian A, Bouchlaka MN, Sckisel GD, Chen M, Pai CC, Maverakis E, Spencer RG, Fishbein KW, Siddiqui S, Monjazeb AM, Martin B, Maudsley S, Hesdorffer C, Ferrucci L, Longo DL, Blazar BR, Wiltrout RH, Taub DD, Murphy WJ. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J Exp Med. 2014 Nov 17; 211(12):2373-83. PMID: 25366964; PMCID: PMC4235633.
    20. Canter RJ, Ames E, Mac S, Grossenbacher SK, Chen M, Li CS, Borys D, Smith RC, Tellez J, Sayers TJ, Monjazeb AM, Murphy WJ. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer. 2014 Oct 10; 14:756. PMID: 25301268; PMCID: PMC4200119.
    21. Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov; 124(11):4867-76. PMID: 25271622; PMCID: PMC4347242.
    22. Perez-Cunningham J, Ames E, Smith RC, Peter AK, Naidu R, Nolta JA, Murphy WJ. Natural killer cell subsets differentially reject embryonic stem cells based on licensing. Transplantation. 2014 May 27; 97(10):992-8. PMID: 24704665.
      View in: PubMed
    23. Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Dubovsky JA, Byrd JC, MacDonald KP, Hill GR, Blazar BR. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98. PMID: 24820310; PMCID: PMC4064335.
    24. Bouchlaka MN, Sckisel GD, Chen M, Mirsoian A, Zamora AE, Maverakis E, Wilkins DE, Alderson KL, Hsiao HH, Weiss JM, Monjazeb AM, Hesdorffer C, Ferrucci L, Longo DL, Blazar BR, Wiltrout RH, Redelman D, Taub DD, Murphy WJ. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med. 2013 Oct 21; 210(11):2223-37. PMID: 24081947.
      View in: PubMed
    25. Alvarez M, Sungur CM, Ames E, Anderson SK, Pomeroy C, Murphy WJ. Contrasting effects of anti-Ly49A due to MHC class I cis binding on NK cell-mediated allogeneic bone marrow cell resistance. J Immunol. 2013 Jul 15; 191(2):688-98. PMID: 23752612; PMCID: PMC3733663.
    26. Sungur CM, Tang-Feldman YJ, Ames E, Alvarez M, Chen M, Longo DL, Pomeroy C, Murphy WJ. Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. Proc Natl Acad Sci U S A. 2013 Apr 30; 110(18):7401-6. PMID: 23589894; PMCID: PMC3645578.
    27. Sun K, Hsiao HH, Li M, Ames E, Bouchlaka M, Welniak LA, Hagino T, Jagdeo J, Pai CC, Chen M, Blazar BR, Abedi M, Murphy WJ. IFN-? receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation. J Immunol. 2012 Aug 15; 189(4):2033-42. PMID: 22778394; PMCID: PMC3509544.
    28. Murphy WJ, Nolta JA. Autoimmune T cells lured to a FASL web of death by MSCs. Cell Stem Cell. 2012 May 04; 10(5):485-7. PMID: 22560070.
      View in: PubMed
    29. Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH, Longo DL, Lanier LL, Blazar BR, Redelman D, Murphy WJ. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood. 2012 Mar 29; 119(13):3073-83. PMID: 22251483; PMCID: PMC3321869.
    30. Murphy WJ, Parham P, Miller JS. NK cells--from bench to clinic. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S2-7. PMID: 22226108; PMCID: PMC3260456.
    31. Sun K, Alvarez M, Ames E, Barao I, Chen M, Longo DL, Redelman D, Murphy WJ. Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood. 2012 Feb 09; 119(6):1590-8. PMID: 22184406; PMCID: PMC3286220.
    32. Ames E, Harouna S, Meyer C, Welniak LA, Murphy WJ. The triterpenoid CDDO-Me promotes hematopoietic progenitor expansion and myelopoiesis in mice. Biol Blood Marrow Transplant. 2012 Mar; 18(3):396-405. PMID: 22100978; PMCID: PMC3502000.
    33. Taub DD, Murphy WJ, Longo DL. Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways. Curr Opin Pharmacol. 2010 Aug; 10(4):408-24. PMID: 20595009.
      View in: PubMed
    34. Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, Bishop MR, Blazar BR, Falkenburg JH. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant. 2010 May; 16(5):565-86. PMID: 20152921; PMCID: PMC2858433.
    35. Murphy WJ, Artz AS, Champlin RE, Koreth J, Longo DL, van den Brink MR. Blood stem cell transplantation in older patients. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1638-9. PMID: 19911448.
      View in: PubMed
    36. Koreth J, Alyea EP, Murphy WJ, Welniak LA. Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1502-12. PMID: 19896073; PMCID: PMC3501140.
    37. Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR, Wiltrout RH, Welniak LA, Redelman D, Murphy WJ. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med. 2007 Mar; 13(3):354-60. PMID: 17334371.
      View in: PubMed
    38. Raziuddin A, Longo DL, Bennett M, Winkler-Pickett R, Ortaldo JR, Murphy WJ. Increased bone marrow allograft rejection by depletion of NK cells expressing inhibitory Ly49 NK receptors for donor class I antigens. Blood. 2002 Oct 15; 100(8):3026-33. PMID: 12351417.
      View in: PubMed
    39. Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, Fanslow WC, Boyd A, Taub DD, Durum SK, Siegall CB, Longo DL, Murphy WJ. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood. 2002 Jul 01; 100(1):217-23. PMID: 12070030.
      View in: PubMed